Literature DB >> 31502864

Treatment of Mycoplasma pneumoniae-Induced Rash and Mucositis With Cyclosporine [Formula: see text].

Heidi Oi-Yee Li1, Sophia Colantonio1, Michele L Ramien2,3.   

Abstract

BACKGROUND: Mycoplasma pneumoniae-induced rash and mucositis (MIRM) is a relatively newly recognized clinical entity that typically presents with predominant mucositis accompanied by variable cutaneous involvement 7-9 days after the onset of prodromal symptoms. There are no evidence-based guidelines for treatment, and current standards of care may include supportive therapy, antibiotics, corticosteroids, and intravenous immunoglobulin .
OBJECTIVE: This case series aims to describe the potential efficacy of cyclosporine A (CsA) in the treatment of MIRM.
METHODS: The present case series details our use of CsA early in the course of MIRM in 3 pediatric patients.
RESULTS: Rapid clinical resolution was observed following CsA therapy.
CONCLUSIONS: We suggest that early initiation of CsA may be an effective therapeutic option for MIRM.

Entities:  

Keywords:  Fuchs syndrome; MIRM; MPAM; Mycoplasma pneumoniae-associated mucositis; Mycoplasma pneumoniae-induced rash and mucositis; SJS; Stevens-Johnson syndrome; case series; cyclosporine; cyclosporine A; mucositis; mycoplasma; pediatric; therapeutics

Mesh:

Substances:

Year:  2019        PMID: 31502864     DOI: 10.1177/1203475419874444

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN: 1203-4754            Impact factor:   2.092


  7 in total

1.  Mycoplasma Pneumoniae Induced Rash and Mucositis with Bilateral Otitis Media and Sinusitis.

Authors:  Daniel H Lofgren; Christopher Lenkeit; Jaishree Palanisamy; Jens Brown
Journal:  Cureus       Date:  2020-03-28

Review 2.  [Viral exanthems in children].

Authors:  Julia E Fromme; Iliana Tantcheva-Poór; Regina Fölster-Holst
Journal:  Hautarzt       Date:  2022-05-25       Impact factor: 1.198

3.  Clonal expansion of CD4+CD8+ T cells in an adult patient with Mycoplasma pneumoniae-associated Erythema multiforme majus.

Authors:  Sarah M Volkers; Christian Meisel; Dorothea Terhorst-Molawi; Guido J Burbach; Dirk Schürmann; Norbert Suttorp; Leif E Sander
Journal:  Allergy Asthma Clin Immunol       Date:  2021-02-10       Impact factor: 3.406

4.  Case Report and Literature Review: Clinical Characteristics of 10 Children With Mycoplasma pneumoniae-Induced Rash and Mucositis.

Authors:  Ning Chen; Miao Li
Journal:  Front Pediatr       Date:  2022-03-03       Impact factor: 3.418

5.  Reactive infectious mucocutaneous eruption - repeat etanercept after intravenous immunoglobulin: A case report.

Authors:  Rochelle Tonkin; Malika Ladha; Nicole Johnson; William F Astle; Ami Britton; Neil H Shear; Luis Murguía-Favela; Michele Ramien
Journal:  SAGE Open Med Case Rep       Date:  2022-08-17

6.  Reactive infectious mucocutaneous eruption following COVID-19 in an adolescent boy: Case report and review of the literature.

Authors:  Ayisha Mahama; Priscilla Kojder; Quinn Thibodeaux; Jennifer Ruth
Journal:  Pediatr Dermatol       Date:  2022-08-30       Impact factor: 1.997

7.  Reactive infectious mucocutaneous eruption secondary to SARS-CoV-2.

Authors:  C Yoonhee Ryder; Elisabeth A Pedersen; Jennifer B Mancuso
Journal:  JAAD Case Rep       Date:  2021-10-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.